Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

4:08 PM ET 8-K
Financial Results Inovio Pharmaceuticals, Inc. INO

Inovio Pharmaceuticals Financial Results

INOVIO reported Q3 2026 financial results and highlighted the landmark FDA accelerated approval of VOCERYQ, the first-ever approved DNA medicine, for the treatment of Recurrent Respiratory Papillomatosis (RRP). The company recently completed a public offering raising $80.5 million in net proceeds to support the commercial launch of VOCERYQ, which is expected to be available for order in early 2027.

“We are delighted with the recent approval of VOCERYQ, which FDA described as a groundbreaking therapy that fights RRP at its source, not only its symptoms. INOVIO is now a commercial stage company with a primary goal to establish VOCERYQ as the preferred first-line immunotherapy for RRP patients.”

Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer

“Our recently completed public offering provides additional financial resources to support a successful launch. Furthermore, this approval validates our DNA medicine platform and we are actively seeking partnerships to accelerate the development of other exciting candidates within our pipeline”

Dr. Jacqueline Shea, INOVIO’s President and Chief Executive Officer
4:08 PM ET 8-K
Financial Results Beachbody Company, Inc. BODI

Beachbody Company Financial Results

Beachbody (BODi) reported its fifth consecutive quarter of net income and operating income for Q3 2026, with net income and Adjusted EBITDA exceeding the high end of guidance. While total revenue declined to $45.2 million from $59.9 million year-over-year, the company maintained a 70.7% gross margin and achieved its twelfth consecutive quarter of positive Adjusted EBITDA.

Term
Q3 2026

“Net income and adjusted EBITDA exceeded the high end of our guidance and revenue met expectations as we continue to transform our business model. As the proactive wellness company delivering nutrition, supplements and proven fitness programs that help people take control of their health, we are executing on our omni-channel strategy to place our iconic brands wherever shoppers are.”

Carl Daikeler, co-founder and BODi’s Chief Executive Officer

“Our third quarter results mark our twelfth consecutive quarter of positive Adjusted EBITDA and our fifth consecutive quarter of double-digit Adjusted EBITDA margins, reflecting the operating discipline we have built into this company.”

Mark Goldston, BODi’s Executive Chairman
4:08 PM ET 10-Q
Financial Results Braveheart Bio, Inc. BRVE

Braveheart Bio Q3 2026 Results: Net Loss of $26.5M, Loss Narrows

Braveheart Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing its lead candidate BHB-1893 for hypertrophic cardiomyopathy (HCM). The company reports a limited operating history with significant losses and expects to require substantial additional funding to support its ongoing clinical trials, including LIONHEART-HCM and TRUEHEART-HCM.

Key figure
Net loss $26.5M
4:08 PM ET 8-K
Financial Results Airgain Inc AIRG

Airgain Financial Results

Airgain reported Q3 2026 revenue of $15.3 million, up 12% sequentially and 9% year-over-year, driven by strong momentum in its enterprise IoT business. The company achieved a non-GAAP net income of $0.5 million and secured new design wins for AI data center infrastructure, though it continues to navigate near-term supply constraints.

Term
Q3 2026

“Airgain delivered another strong quarter of progress, with revenue increasing 12% quarter-over-quarter and 9% year-over-year, driven by continued momentum in our enterprise IoT business.”

Jacob Suen, President and CEO of Airgain

“Our results reflect growing demand across established industrial applications, along with new opportunities in areas such as AI data center infrastructure.”

Jacob Suen, President and CEO of Airgain
4:08 PM ET 8-K
Financial Results Dermata Therapeutics, Inc. DRMA

Dermata Therapeutics Financial Results

Dermata Therapeutics reported financial results for the third quarter of 2026, highlighting its transition to a revenue-generating company following the August 2025 launch of Tome Foundational Treatment. The company reported its first product revenue and noted that approximately 30% of orders were generated via subscriptions.

Term
Q3 2026

“The third quarter represents a transformational time for Dermata as we completed our transition from a development-stage pharmaceutical company to a revenue-generating commercial skincare business.”

Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer

“With the launch of Tome Foundational Treatment on August 25, 2026, we began generating our first product revenue, marking an important step in executing our strategy to build a differentiated skincare brand around BioneedleTM, our hero ingredient, consisting of 100% freshwater sponge, which we wild harvest and minimally process into a fine, purified powder.”

Gerry Proehl, Dermata’s Chairman, President, and Chief Executive Officer
4:07 PM ET 8-K
Financial Results Mobile Infrastructure Corp BEEP

Mobile Infrastructure Financial Results

Mobile Infrastructure Corporation reported its third quarter 2026 financial results, highlighted by a 12.8% increase in same-location revenue and an 18.4% increase in same-location NOI. The company achieved record RevPAS growth of 16% driven by a 13 percentage point improvement in utilization across its parking portfolio.

Term
Q3 2026

“We are pleased with our third quarter results, marking Mobile’s strongest operating quarter of 2026, building strong momentum heading into 2027, and achieving our highest utilization and RevPAS to date.”

Stephanie Hogue, Chief Executive Officer

“At the start of the year, we discussed our strategy of building utilization first, establishing a larger and more durable base of recurring and transient demand, and following this with improved, sustainable pricing as utilization improves. Our results in the third quarter evidence strong execution as our strategy translates into earnings improvement.”

Stephanie Hogue, Chief Executive Officer
4:07 PM ET 8-K
Financial Results QumulusAI, Inc. QMLS

QumulusAI Financial Results

QumulusAI reported third quarter 2026 revenue of $14.8 million, a 376% increase year-over-year, driven by its neocloud compute infrastructure. The company achieved its first positive Adjusted EBITDA of $3.7 million while cumulative signed customer contract value surpassed $500 million following new agreements for NVIDIA Blackwell GPU clusters.

Term
Q3 2026

“Revenue doubled again this quarter, and remaining performance obligations grew to $515.0 million from $173.1 million at the end of the second quarter. That’s the model doing its job: we sell the capacity before we energize it, we deploy into pockets of existing power, and we bring it online in months, not years.”

Michael Maniscalco, CEO of QumulusAI
4:07 PM ET 8-K
Financial Results Fold Holdings, Inc. FLD

Fold Holdings Financial Results

Fold Holdings reported Q3 2026 financial results, highlighting a 270% increase in custody and trading revenue and the launch of Fold Reserve and Lead Bank accounts. The company reduced operating expenses by 21% year-over-year and is transitioning its business model from transaction-based to balance-based economics.

Term
Q3 2026

“We believe Q3 was an inflection point for Fold. Over the last few months we’ve evolved from strictly a transaction-based business to one that also monetizes customer balances, broadened our focus from bitcoin earners to every American who earns rewards, strengthened our balance sheet, maintained a focus on operational efficiency, and opened new distribution channels that take our products to audiences we’ve never reached before.”

Will Reeves, Chairman and CEO

“We are reshaping Fold from a business built on gathering customers into one built on gathering assets. A transaction pays us once. A customer balance earns for us every month it stays on the platform, and it ties that customer more closely to everything else we offer.”

Will Reeves, Chairman and CEO
4:07 PM ET 10-K
Financial Results TransDigm Group INC TDG

TransDigm Group FY 2026 Results: Net Income $2.11B, Up 1.6% YoY

TransDigm Group INC continues to focus on a high-leverage capital structure and proprietary aerospace components, with its top ten customers accounting for 45% of net sales in fiscal 2026. The company operates through three segments—Power & Control, Airframe, and Non-aviation—serving commercial aftermarket, OEM, and defense markets.

Key figure
Net income $2.11B · +1.6% YoY
4:07 PM ET 10-Q
Financial Results Dakota Gold Corp. DC

Dakota Gold Q3 2026 Results: Net Loss of $8.41M, Loss Narrows

Dakota Gold Corp. reported a net loss of $25.23 million for the nine months ended September 30, 2026, compared to $20.70 million in the prior year period. The company significantly strengthened its liquidity position, ending the period with $92.15 million in cash and cash equivalents following successful common stock offerings and warrant exercises.

Key figure
Net loss $8.41M
4:07 PM ET 10-Q
Financial Results Grayscale Hyperliquid Staking ETF HYPG

Grayscale Hyperliquid Staking ETF Q2 2026 Results: Net Income $52M

The Grayscale Hyperliquid Staking ETF commenced operations on June 3, 2026, and held 2,219,189.85 HYPE tokens valued at $196.9 million as of September 30, 2026. The Trust recognizes staking rewards as revenue on a net basis under ASC 606 and distributed $368,736 in cash to shareholders from these rewards during the quarter.

Key figure
Net income $52M
4:07 PM ET 10-Q
Financial Results Gladstone Land Corp LAND

Gladstone Land Q3 2026 Results: Net Income $11M, Up 428.3% YoY

For the quarter ended September 30, 2026, Gladstone Land reported total operating revenues of $31.5 million and net income attributable to common stockholders of $6.1 million, a significant improvement from the prior year's quarterly loss. However, for the nine-month period, the company recorded a net loss of $17.4 million, primarily driven by higher impairment charges and property operating expenses.

Key figure
Net income $11M · +428.3% YoY
4:07 PM ET 10-Q
Financial Results Ambow Education Holding Ltd. AMBO

Ambow Education Holding Q3 2026 Results: Net Loss of $773K, Loss Widens

Ambow Education Holding Ltd. reported total net revenues of $6.85 million for the nine months ended September 30, 2026, a slight increase from $6.48 million in the prior year. The company experienced a net loss of $0.50 million for the period compared to a net income of $1.27 million in 2025, primarily driven by higher operating expenses and the absence of a prior-year gain on lease settlement.

Key figure
Net loss $773K
4:07 PM ET 10-Q
Financial Results Anteris Technologies Global Corp. AVR

Anteris Technologies Global Q3 2026 Results: Net Loss of $26.8M, Loss Widens

Anteris Technologies Global Corp. reported a net loss of $78.5 million for the nine months ended September 30, 2026, driven by significant research and development expenses of $62.2 million. The company's financial position improved substantially during the period, with cash and cash equivalents increasing to $232.8 million following the issuance of common stock, resulting in a total stockholders' equity of $226.8 million.

Key figure
Net loss $26.8M
4:07 PM ET 10-Q
Financial Results Co-Diagnostics, Inc. CODX

Co-Diagnostics Q3 2026 Results: Net Loss of $6.31M, Loss Widens

Co-Diagnostics, Inc. reported a net loss of $21.7 million for the nine months ended September 30, 2026, compared to a $21.2 million loss in the prior year. Total revenue increased to $594,966 from $358,567, while cash and cash equivalents significantly decreased to $714,803 from $11.9 million at the start of the year.

Key figure
Net loss $6.31M
4:07 PM ET 8-K
Financial Results CoreWeave, Inc. CRWV

CoreWeave Financial Results

CoreWeave reported record third quarter 2026 revenue of $3.66 billion, a significant increase from $1.37 billion in the prior year, driven by massive demand for AI infrastructure. Despite the revenue growth, the company reported a net loss of $709 million due to high interest expenses and rapid scaling costs. Management highlighted a revenue backlog of $132.5 billion and plans to receive $9 billion in customer prepayments over the next three months.

Term
Q3 2026

“This was a breakout quarter for CoreWeave, with revenue increasing by more than $1 billion sequentially and adjusted operating margins reaching double digits a quarter ahead of plan.”

Michael Intrator, co-founder, chairman and chief executive officer of CoreWeave

“Our growth is supported by multiple sources of funding, including financing backed by customer contracts, operating cash flow, and approximately $9 billion in customer prepayments and deposits expected in the next three months alone.”

Michael Intrator, co-founder, chairman and chief executive officer of CoreWeave
4:07 PM ET 10-Q
Financial Results Fortitude Gold Corp FTCO

Fortitude Gold Q3 2026 Results: Net Income $1.96M, Up 741.6% YoY

Fortitude Gold Corp reported a net loss of $4.4 million for the nine months ended September 30, 2026, compared to a net income of $2.3 million in the prior year, primarily driven by a significant increase in exploration and reclamation expenses. Despite the loss, the company strengthened its cash position to $8.5 million through a $17.2 million stock issuance and $5.5 million in funding from noncontrolling interests.

Key figure
Net income $1.96M · +741.6% YoY
4:07 PM ET 8-K
Financial Results Freenome, Inc. FRNM

Freenome Financial Results

Freenome reported its first quarterly results as a public company, highlighted by $183.5 million in revenue following the FDA approval of its SimpleScreen CRC blood test. The company achieved GAAP net income of $60.1 million, a significant turnaround from a net loss in the prior year, and ended the quarter with $430 million in cash and marketable securities.

Term
Q3 2026

“Freenome made meaningful progress in its first quarter as a public company, executing on our strategic partnerships and strengthening our operating foundation.”

Aaron Elliott, Ph.D., CEO of Freenome
4:07 PM ET 10-Q
Financial Results Access Newswire Inc. ACCS ▶ Call

Access Newswire Q3 2026 Results: Net Loss of $80K, Loss Widens

ACCESS Newswire Inc. reported a net loss of $1.17 million for the nine months ended September 30, 2026, compared to a net income of $4.87 million in the prior year period, which was bolstered by discontinued operations. Total revenues decreased slightly to $16.46 million from $16.82 million year-over-year, while the company maintained a cash balance of approximately $2.99 million.

Key figure
Net loss $80K
4:07 PM ET 8-K
Financial Results Orion180 Insurance Group Inc. OIG

Orion180 Insurance Group Financial Results

Orion180 Insurance Group reported third quarter 2026 financial results, highlighted by a 32% increase in net income to $11.5 million and a 60% growth in managed premiums written to $204 million. The quarter marked the company's first as a public entity following its IPO in September 2026, with managed premiums in-force reaching $678 million.

Term
Q3 2026

“We delivered an excellent quarter across our key metrics, rapidly growing our managed premiums while significantly increasing our profitability on a year-over-year basis. In addition, we achieved a major milestone in our Company’s history by successfully completing our initial public offering. We believe our results reflect the strength, differentiation and scalability of the business model we have built over the past eight years.”

Kenneth Gregg, Chief Executive Officer of Orion180

“We are well-positioned to produce durable growth on both our top and bottom lines, which is driven by our attractive suite of homeowners solutions - including our flagship FLEX product - as well as our proprietary end-to-end MY180 tech platform, which allows us to seamlessly combine best-in-class underwriting, claims management, and real-time analytic capabilities.”

Kenneth Gregg, Chief Executive Officer of Orion180
4:07 PM ET 8-K
Financial Results Lumexa Imaging Holdings, Inc. LMRI

Lumexa Imaging Holdings Financial Results

Lumexa Imaging reported Q3 2026 financial results with revenue growing 5% to $272.0 million and net income of $7.2 million. The company reiterated its full-year revenue guidance while raising its Adjusted EPS outlook to $0.86–$0.90 due to a lower effective tax rate.

Term
Q3 2026

“In Q3, we advanced our business in several meaningful ways while executing against our strategy. Advanced modalities reached a record high as a percent of our volumes, and our newer de novo cohorts continue to ramp on plan. We are actively opening three new de novo centers and are on pace to achieve our goal for 8–10 new center openings this year.”

Caitlin Zulla, Chief Executive Officer of Lumexa Imaging

“We are leading a transformation in healthcare - delivering high-quality imaging in more convenient settings, more quickly and at meaningfully lower cost through our wholly owned centers and alongside health system partners, improving clinical and financial outcomes.”

Caitlin Zulla, Chief Executive Officer of Lumexa Imaging
4:07 PM ET 8-K
Financial Results Velo3D, Inc. VELO

Velo3D Financial Results

Velo3D reported Q3 2026 revenue of $20.5 million, a 50% year-over-year increase, driven by strong demand in aerospace and defense sectors. The company reported a GAAP net loss of $16.7 million as it invested in scaling its new Livermore Production Campus, Forge 1, which is expected to serve as its primary manufacturing center.

Term
Q3 2026

“We delivered solid third quarter results, with revenue increasing approximately 50% year-over-year to $20.5 million and new bookings reaching $28.9 million, exceeding revenue for the quarter. These results reflect continued customer demand for our metal additive manufacturing technology and the progress we are making in executing our growth strategy.”

Arun Jeldi, Chief Executive Officer of Velo3D

“Looking ahead, Forge 1 is central to Velo3D’s next phase of growth and is expected to significantly expand our production capacity as it becomes fully operational, enabling us to pursue larger production programs and capture opportunities across aerospace, defense, space and energy.”

Arun Jeldi, Chief Executive Officer of Velo3D
4:07 PM ET 8-K
Financial Results Gain Therapeutics, Inc. GANX

Gain Therapeutics Financial Results

Gain Therapeutics reported financial results for the third quarter of 2026, highlighted by long-term Phase 1b data for rexaceract showing no motor symptom progression in Parkinson’s disease patients over 12 months. The company plans to initiate a Phase 2 clinical trial for rexaceract in Q1 2027 and select an initial therapeutic indication for its second candidate, GT-04686, by the end of 2026.

Term
Q3 2026

“The third quarter marked an important period of progress for Gain, highlighted by the presentation of long-term open-label data from the Phase 1b trial of rexaceract in Parkinson’s disease (PD). After 12 months of dosing with rexaceract, participants enrolled in the study showed no progression of Parkinson’s disease motor symptoms.”

Gene Mack, President and CEO of Gain Therapeutics

“As we approach the start of the Phase 2 clinical trial of rexaceract, which we expect to initiate during Q1 2027 after confirming updates to our trial design during Q4 2026, we plan to select an initial therapeutic indication to advance GT-04686 into the clinic.”

Gene Mack, President and CEO of Gain Therapeutics
4:07 PM ET 8-K
Financial Results Rigetti Computing, Inc. RGTI

Rigetti Computing Financial Results

Rigetti Computing reported Q3 2026 financial results, highlighted by $1.4 million in quarterly revenue and a strong cash position of $497.1 million. The company achieved a key technical milestone with 99.5% median two-qubit fidelity on its 108-qubit system and signed a $100 million agreement with the U.S. Department of Commerce.

Term
Q3 2026

“Rigetti delivered meaningful progress during the third quarter across system performance, technology development and strategic execution. Our Cepheus-1-108Q system achieved our goal of 99.5% median two-qubit gate fidelity, demonstrating continued performance improvement at the 100-plus-qubit level and further validating our chiplet-based approach to scaling superconducting quantum computers.”

Dr. Subodh Kulkarni, Rigetti CEO

“We also signed a definitive $100 million agreement with the U.S. Department of Commerce. Building on the progress achieved this quarter, our next major system objective is to demonstrate a 300-plus-qubit system with approximately 99.7% median two-qubit gate fidelity and gate speeds below 60 nanoseconds by mid-2028.”

Dr. Subodh Kulkarni, Rigetti CEO
4:06 PM ET 8-K
Financial Results B&G Foods, Inc. BGS

B&G Foods Financial Results

B&G Foods reported third quarter 2026 financial results, featuring a 4.7% increase in net sales to $459.8 million and 5.0% growth in base business net sales. The company raised its full-year 2026 net sales and Adjusted EBITDA guidance while reporting a net loss of $32.5 million for the quarter.

Term
Q3 2026

“Third quarter and year-to-date results reflect encouraging progress across B&G Foods. We generated base business net sales growth of 5.0% in the third quarter and 1.8% year-to-date, while adjusted EBITDA increased $12.4 million, or 6.6%, year-to-date. We are encouraged by this progress and remain focused on building on it.”

Rob Mills, President and Chief Executive Officer

“As we look ahead, our priorities are clear: deliver on our 2026 commitments; build a stronger operating foundation for 2027 and beyond; accelerate productivity and cost savings; improve cash generation; and reduce leverage. We are taking deliberate actions to strengthen B&G Foods, improve financial flexibility and position our company for sustainable long-term performance.”

Rob Mills, President and Chief Executive Officer
4:06 PM ET 10-Q
Financial Results Alliance Laundry Holdings Inc. ALH ▶ Call

Alliance Laundry Holdings Q3 2026 Results: Net Income $65.1M, Up 98.0% YoY

Alliance Laundry Holdings Inc. reported a significant increase in net income for the nine months ended September 30, 2026, reaching $190.7 million compared to $81.2 million in the prior year. This growth was driven by higher net revenues of $1.36 billion and a substantial reduction in interest expense, which fell from $121.2 million to $52.3 million year-over-year.

Key figure
Net income $65.1M · +98.0% YoY
4:06 PM ET 8-K
Financial Results Kura Oncology, Inc. KURA

Kura Oncology Financial Results

Kura Oncology reported Q3 2026 financial results, highlighted by $13.9 million in net product revenue for KOMZIFTI, representing 53% sequential growth. The company reached FDA alignment on a registrational study design for darlifarnib in salivary gland cancer and secured a strategic financing agreement with Oberland Capital for up to $300 million.

Term
Q3 2026

“KOMZIFTI delivered strong commercial performance this quarter, with 53% sequential revenue growth, a 30% increase in new patients starts, and continued majority share of new patient starts. We believe these results demonstrate the growing commercial potential of KOMZIFTI and provide a strong foundation as we advance ziftomenib into the substantially larger frontline AML opportunity.”

Troy Wilson, Ph.D., J.D., President and Chief Executive Officer
4:06 PM ET 10-Q
Financial Results Grayscale Horizen Trust (ZEN) HZEN

Grayscale Horizen Trust Q3 2026 Results: Net Income $3M, Up 679.7% YoY

Grayscale Horizen Trust reported a net decrease in net assets from operations of $1.893 million for the nine months ended September 30, 2026, primarily driven by unrealized depreciation of its ZEN holdings. The Trust's net assets fell to $6.780 million from $8.673 million at the start of the year, with the Principal Market NAV per Share declining from $0.76 to $0.59.

Key figure
Net income $3M · +679.7% YoY
4:06 PM ET 8-K
Financial Results Carlsmed, Inc. CARL

Carlsmed Financial Results

Carlsmed reported Q3 2026 revenue of $21.6 million, a 65% increase year-over-year, driven by a 60% expansion of its surgeon user base. The company raised its full-year 2026 revenue guidance to $78-$80 million and highlighted new CMS inpatient reimbursement for its aprevo lumbar spine fusion procedure.

Term
Q3 2026

“The third quarter represented strong execution against our long-term strategy as we delivered 65% revenue growth and advanced our leadership position in AI-enabled personalized surgery as we grew our surgeon user base by more than 60% over the prior year.”

Mike Cordonnier, Chairman and CEO

“We broadened our personalized surgery platform, strengthened our leadership team, and secured new inpatient CMS reimbursement for our aprevo® lumbar spine fusion procedure. Taken together with our differentiated, capital-light model, these accomplishments reinforce our foundation for sustainable, profitable long-term growth as we head into 2027.”

Mike Cordonnier, Chairman and CEO
4:06 PM ET 8-K
Financial Results Capricor Therapeutics, Inc. CAPR

Capricor Therapeutics Financial Results

Capricor Therapeutics reported Q3 2026 financial results and provided a regulatory update on its BLA for Deramiocel in Duchenne muscular dystrophy, which has a PDUFA date of November 22, 2026. The company ended the quarter with approximately $199 million in cash and marketable securities. Management highlighted clinical data showing a 76% slowing of upper limb decline in patients who switched to Deramiocel during the HOPE-3 open-label extension.

Term
Q3 2026

“This quarter, we took important steps forward on both our regulatory filing and our launch readiness, submitting two-year HOPE-3 OLE data in a major amendment to our BLA while advancing our manufacturing and commercial preparations. In the OLE phase, patients who switched from placebo to Deramiocel saw their upper limb decline slow by 76% compared with their year on placebo, and this past weekend our HOPE-3 cardiac results received the AHA Outstanding Research Award in Pediatric Cardiology.”

Linda Marbán, Ph.D., Capricor’s Chief Executive Officer

“As Duchenne progresses, boys and young men lose the use of their arms and hands, and with it their independence, which is what Deramiocel is designed to slow. We appreciate the FDA’s engagement throughout this review and are encouraged by the Agency’s current focus on rare disease, including its recently launched Rare Disease Framework Initiative. As we approach our PDUFA date, we remain confident in the strength of our data. With our San Diego facility operational, we are prepared to move quickly to bring Deramiocel to patients, if approved.”

Linda Marbán, Ph.D., Capricor’s Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.